Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

(CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000

NCT07680244 is registered in ClinicalTrials.gov with Carl Zeiss Meditec-Dublin CoCe as lead sponsor.

NCT NCT07680244
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07680244 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
(CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000
Lead sponsor
Carl Zeiss Meditec-Dublin CoCe
Phase
Not applicable
Overall status
Recruiting
Start date
May 23, 2025
Completion date
August 31, 2026
Enrollment
400 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

dry age related macular degeneration, epiretinal membrane, intraretinal hyporeflective space, is/os (ellipsoid zone) disruption, macular abnormalities, retina disease, retinal pigment epithelium (rpe) atrophy, retinal pigment epithelium (rpe) elevation, subretinal hyporeflective space, vitreoretinal abnormality